Kinetics and mechanism of the reaction of aminoguanidine with the α-oxoaldehydes glyoxal, methylglyoxal, and 3-deoxyglucosone under physiological conditions

Biochemical Pharmacology

Volumn 60, Issue 1, 2000, Pages 55-65

  Thornalley, Paul J ^a   Yurek George, Alexander ^a   Argirov, Ongian K ^a  

^a UNIVERSITY OF ESSEX   (United Kingdom)

Author keywords

3 Deoxyglucosone; Aminoguanidine; Diabetic complications; Glycation; Glyoxal; Methylglyoxal

Indexed keywords

1,2,4 TRIAZINE DERIVATIVE; 3 DEOXYGLUCOSONE; AMINOGUANIDINE; GLYOXAL; METHYLGLYOXAL; UNCLASSIFIED DRUG;

ARTICLE; CHEMICAL REACTION KINETICS; DIABETES MELLITUS; IN VITRO STUDY; PRIORITY JOURNAL; REACTION ANALYSIS; SPECTROPHOTOMETRY;

DEOXYGLUCOSE; ENZYME INHIBITORS; GLYOXAL; GUANIDINES; KINETICS; PYRUVALDEHYDE; SPECTROPHOTOMETRY; TRIAZINES;

EID: 0034107785     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(00)00287-2     Document Type: Article

References (45)

1. Thornalley PJ, Clinical significance of glycation. Clin Lab5-6: 263-273, 1999.
2. McCance D.R., Dyer D.G., Dunn J.A., Bailie K.E., Thorpe S.R., Baynes J.W., Lyons T.J. Maillard reaction products and their relation to complications in insulin-dependent diabetes mellitus. J Clin Invest. 91:1993;2470-2478.
3. Lyons T.J., Silvestri G., Dunn J.A., Dyer D.G., Baynes J.W. Role of glycation in modification of lens crystallins in diabetic and nondiabetic senile cataracts. Diabetes. 40:1991;1010-1015.
4. Vitek M.P., Bhattyacharya K., Glendening J.M., Stopa E., Vlassara H., Bucala R., Manogue K., Cerami A. Advanced glycation end products contribute to amyloidosis in Alzheimer disease. Proc Natl Acad Sci USA. 91:1994;4766-4770.
5. 2-Microglobulin modified with advanced glycation end products is a major component of haemodialysis-associated amyloidosis. J Clin Invest. 92:1993;1242-1252.
6. Vlassara H., Fuh H., Makita Z., Krungkrai S., Cerami A., Bucala R. Exogenous advanced glycosylation end products induce complex vascular dysfunction in normal animals A model for diabetic and aging complications. Proc Natl Acad Sci U S A. 89:1992;12043-12047.
7. Lo T.W., Selwood T., Thornalley P.J. Reaction of methylglyoxal with aminoguanidine under physiological conditions and prevention of methylglyoxal binding to plasma proteins. Biochem Pharmacol. 48:1994;1865-1870.
8. Hirsch J., Petrakova E., Feather M.S. The reaction of some dicarbonyl sugars with aminoguanidine. Carbohydr Res. 232:1992;125-130.
9. Chen H.-J.C., Cerami A. Mechanism of inhibition of advanced glycosylation by aminoguanidine in vitro. J Carbohydr Chem. 12:1993;731-742.
10. Soulis T., Thallas V., Toussef S., Gilbert R.E., McWilliam B.G., Murray-McIntosh R.P., Cooper M.E. Advanced glycation end products and their receptors co-localise in rat organs susceptible to diabetic vascular injury. Diabetologia. 40:1997;619-628.
11. Hammes H.P., Martin S., Federlin K., Geisen K., Brownlee M. Aminoguanidine treatment inhibits the development of experimental diabetic retinopathy. Proc Natl Acad Sci U S A. 88:1991;11555-11558.
12. Araki A, Glomb MA, Takahashi M and Monnier VM, Determination of dicarbonyl compounds as aminotriazines during the Maillard reaction and in vivo detection in aminoguanidine-treated rats. In: The Maillard Reaction in Foods and Medicine (Eds. O'Brien J, Nursten HE, Crabbe MJ and Ames JM), p. 400. RSC Publ., Cambridge, U.K., 1998.
13. McLellan A.C., Thornalley P.J. Synthesis and chromatography of 1,2-diamino-4,5-dimethoxybenzene, 6,7-dimethoxy-2-methylquinoxaline and 6,7-dimethoxy-2,3-dimethylquinoxaline for use in a liquid chromatographic fluorimetric assay of methylglyoxal. Anal Chim Acta. 263:1992;137-142.
14. Madson M.A., Feather M.S. An improved preparation of 3-deoxy-D-erthyro-hexos-2-ulose via the bis(benzoylhydrazone) and some related constitutional studies. Carbohydr Res. 94:1981;183-191.
15. Mendes P. GEPASI A software package for modelling the dynamics, steady states and control of biochemical and other systems. Comput Appl Biosci. 9:1993;563-571.
16. Daunis J., Jacquier R., Viallefont P. Etude en serie as-triazine. IV. Syntheses de triazine-1,2,4 substituees en position 3. Bull Soc Chim Fr. 10:1969;3675-3678.
17. Baiocchi F., Cheng C.C., Haggerty W.J. Jr, Lewis L.L., Liao T.K., Nyberg W.H., O'Brien D.E., Podrebarac E.G. Studies on methylglyoxal bis(guanylhydrazone) analogs. II. Structural variations on methylglyoxal bis(guanylhydrazone). J Med Chem. 6:1963;431-435.
18. 1NMR and a computer model. Eur J Biochem. 193:1990;83-90.
19. Creighton D.J., Migliorini M., Pourmotabbed T., Guha M.K. Optimisation of efficiency in the glyoxalase pathway. Biochemistry. 27:1988;7376-7384.
20. Betterton E., Hoffmann M. Henry's law constants of some environmentally important aldehydes. Environm Sci Technol. 22:1988;1415-1418.
21. Whipple E.B. The structure of glyoxal in water. J Am Chem Soc. 92:1970;7183-7186.
22. Weenen H., Tjan S.B. Analysis, structure, and reactivity of 3-deoxyglucosone. ACS Symp Ser. 490:1992;217-231.
23. Edwards A.S., Wedzicha B.L. Kinetics and mechanism of the reaction between 3-deoxyglucosone and thiols. Food Addit Contam. 9:1992;461-469.
24. α-acetyl-lysine, and bovine serum albumin. J Biol Chem. 269:1994;32299-32305.
25. Nyengaard J.R., Chang K., Berhorst S., Reiser K.M., Williamson J.R., Tilton R.G. Discordant effect of guanidines on renal structure and function and on regional vascular dysfunction and collagen changes in diabetic rats. Diabetes. 46:1997;94-106.
26. Thornalley P.J. The glyoxalase system in health and disease. Mol Aspects Med. 14:1993;287-371.
27. Chibber R., Molinatti G.M., Wong J.S., Mirlees D., Kohner E.M. The effect of aminoguanidine and tolrestat on glucose toxicity in bovine retinal capillary pericytes. Diabetes. 43:1994;758-763.
28. Bucala R., Makita Z., Koschinsky T., Cerami A., Vlassara H. Lipid advanced glycosylation Pathway for lipid oxidation in vivo. Proc Natl Acad Sci USA. 90:1993;6434-6438.
29. Patthy L. Role of nascent α-ketoaldehyde in substrate-dependent oxidative inactivation of aldolase. Eur J Biochem. 88:1978;181-196.
30. Lal S., Kappler F., Walker M., Orchard T.J., Beisswenger P.J., Szwergold B.S., Brown T.R. Quantitation of 3-deoxyglucosone levels in human plasma. Arch Biochem Biophys. 342:1997;254-260.
31. Beisswenger P.J., Howell S., Touchette A., Lal S., Szwergold B.S. Metformin reduces systemic methylglyoxal levels in type 2 diabetes. Diabetes. 48:1999;198-202.
32. Thornalley P.J., Minhas H.S. Rapid hydrolysis and slow α,β-dicarbonyl cleavage of an agent proposed to cleave glucose-derived protein cross-links. Biochem Pharmacol. 57:1999;303-307.
33. Thornalley P.J. Modification of the glyoxalase system in human red blood cells by glucose in vitro. Biochem J. 254:1988;751-755.
34. Abordo E.A., Minhas H.S., Thornalley P.J. Accumulation of α-oxoaldehydes during oxidative stress A role in cytotoxicity. Biochem Pharmacol. 58:1999;641-648.
35. Westwood M.E., Thornalley P.J. Glycation and advanced glycation endproducts. Colaco C. The Glycation Hypothesis of Atherosclerosis. 1997;57-88 Landes Bioscience, Austin.
36. Corbett J.A., Tilton R.G., Chang K., Hasan K.S., Ido Y., Wang J.L., Sweetland M.A., Lancaster J.R. Jr, Williamson J.R., McDaniel M.L. Aminoguanidine, a novel inhibitor of nitric oxide formation, prevents diabetic vascular dysfunction. Diabetes. 41:1992;552-556.
37. Al-Abed Y., Bucala R. Efficient scavenging of fatty acid oxidation products by aminoguanidine. Chem Res Toxicol. 10:1997;875-879.
38. Giardino I., Fard A.K., Hatchell D.L., Brownlee M. Aminoguanidine inhibits reactive oxygen species formation, lipid peroxidation, and oxidant-induced apoptosis. Diabetes. 47:1998;1114-1120.
39. 1 growth arrest and induction of apoptosis. Leuk Res. 20:1996;397-405.
40. Okado A., Kawasaki Y., Hasuike Y., Takahashi M., Teshima T., Fujii J., Taniguchi N. Induction of apoptotic cell death by methylglyoxal and 3-deoxyglucosone in macrophage-derived cell lines. Biochem Biophys Res Commun. 225:1996;219-224.
41. Hammes H.P., Strodter D., Weiss A., Bretzel R.G., Federlin K., Brownlee M. Secondary intervention with aminoguanidine retards the progression of diabetic retinopathy in the rat model. Diabetologia. 38:1995;656-660.
42. Cameron N.E., Cotter M.A., Dines K., Love A. Effects of aminoguanidine on peripheral nerve function and polyol pathway metabolites in streptozotocin-diabetic rats. Diabetologia. 35:1992;946-950.
43. Sugimoto K., Yagihashi S. Effects of aminoguanidine on structural alterations of microvessels in peripheral nerve of streptozotocin diabetic rats. Microvasc Res. 53:1997;105-112.
44. Soulis-Liparota T., Cooper M., Papazoglou D., Clarke B., Jerums G. Retardation by aminoguanidine of development of albuminuria, mesangial expansion, and tissue fluorescence in streptozotocin-induced diabetic rat. Diabetes. 40:1991;1328-1334.
45. Thornalley PJ, Cell activation by glycated proteins. AGE receptors, receptor recognition factors and functional classification of AGEs. Cell Mol Biol (Noisy-le-grand) 44: 1013-1023, 1998.